Dr. John C. Byrd, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 199
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: University of Arkansas College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
PA license MD492190C · OH license 35.079105
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- UPMC PAssavant Pittsburgh, PA
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
- Oncology Hematology Association Inc (202 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 199
- Services billed
- 646
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 334 | 179 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 49 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calquence (acalabrutinib maleate) | 103 |
| Jaypirca (pirtobrutinib) | 26 |
| Amlodipine Besylate Other prescribers in Pittsburgh, PA | 14 |
| Rosuvastatin Calcium Other prescribers in Pittsburgh, PA | 14 |
| Brukinsa (zanubrutinib) | 14 |
| Acyclovir Other prescribers in Pittsburgh, PA | 12 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Pittsburgh, PA | 12 |
| Venclexta (venetoclax) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $3,898 in total to this clinician.
| AbbVie Inc. | $3,625 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $273 |
| Consulting Fee | $3,625 |
|---|---|
| Food and Beverage | $273 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 8, 2025 | Consulting Fee | $3,625 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $141,173 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie Inc. · Active, not recruiting · NCT05753501 - M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreate…
AbbVie Inc. - Phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.